STERIS

STERIS Plc engages in the provision of healthcare and life science product and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Mentor, OH.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

STERIS plc reports 16% revenue growth and anticipates 7-8% growth in fiscal 2024

STERIS plc's Q4 2023 earnings call highlighted strong revenue growth, successful integration of Cantel Medical, and cost synergies exceeding projections. While challenges exist in the AST segment and concerns were raised about labor costs and free cash flow pressure, the outlook for fiscal 2024 indicates potential opportunities for growth.

STERIS plc reports mixed Q2 performance, optimistic about future opportunities

STERIS plc's Q2 2023 earnings call highlighted mixed performance across segments, with strong growth in Healthcare but challenges in the AST and Dental segments. The company remains optimistic about future opportunities, particularly with the Becton, Dickinson deal and updated financial outlook.

STERIS reports Q3 growth, faces margin pressures and supply challenges

STERIS delivered solid revenue growth despite challenges from divestitures and margin pressures.
The company's strategic acquisitions and focus on direct market access position it for future growth.
While facing some headwinds, STERIS remains confident in its long-term growth prospects.
Investors should monitor how the company navigates supply chain strains and capitalizes on bioprocessing demand.

STERIS reports strong Q4 earnings, eyes growth amid challenges

STERIS delivered robust Q4 2023 results with strong revenue growth and net income.
While facing challenges in certain segments, the company remains optimistic about growth opportunities.
Confidence in compliance with EPA regulations and a positive outlook for fiscal 2024.
Strategic capital allocation decisions and cost synergies driving financial performance.

STERIS reports solid Q1 earnings, eyes growth through acquisitions

STERIS' Q1 2024 performance was solid, driven by revenue growth in the healthcare segment. Challenges were seen in the AST and Dental segments due to inventory destocking. The upcoming acquisition and positive growth expectations in Life Sciences present opportunities for future growth.

STERIS reports strong Q2 performance amidst segment challenges

STERIS showcased robust financial performance in Q2 2024, driven by strong organic revenue growth and solid net income. While facing challenges in certain segments, the company remains optimistic about future growth opportunities and is actively managing its debt and cash flow.

STERIS reports strong Q3 earnings, updates 2024 outlook positively

STERIS showcased solid performance in Q3 2024, driven by strong healthcare and life sciences segments. Challenges in AST and Dental segments were noted, with opportunities seen in updated fiscal 2024 outlook and strategic discussions on margin dynamics and expansion.

STERIS reports 7% revenue growth, anticipates margin improvement ahead

STERIS demonstrated solid revenue growth and maintained free cash flow in line with guidance.
While facing margin challenges in certain segments, the company anticipates improvements ahead.
The outlook for organic revenue growth, adjusted EPS, and free cash flow remains positive for the full year.
Overall, STERIS is strategically positioned to capitalize on growth opportunities and address current challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STERIS Plc engages in the provision of healthcare and life science products and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment offers a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Dublin, Ireland.

Steris (STE) came out with quarterly earnings of $2 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $1.90 per share a year ago.

Steris (STE) Q1 Earnings and Revenues Beat Estimates

Medical equipment provider Steris on Tuesday raised its profit forecast for fiscal 2024 after strength in its core healthcare business boosted first-quarter results above Wall Street estimates.

Medical device maker Steris lifts 2024 results view, records quarterly beat

DUBLIN, IRELAND, Aug. 01, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024 first quarter ended June 30, 2023. Revenue as reported for the quarter increased 11% to $1.28 billion compared with $1.16 billion in the first quarter of fiscal 2023. Constant currency organic revenue (see Non-GAAP Financial Measures) also increased 11% for the first quarter of fiscal 2024 as compared to the first quarter of fiscal 2023.

STERIS Announces Financial Results for Fiscal 2024 First Quarter

DUBLIN, IRELAND , July 26, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share. This represents a $0.05 increase in the dividend and the Company's 18th consecutive year of dividend growth. The dividend is payable on September 22, 2023, to shareholders of record at the close of business on September 6, 2023.

STERIS Raises Dividend to $0.52 per share

DUBLIN, IRELAND, July 19, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 first quarter financial results at 9:00 a.m. ET on August 2, 2023. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.

STERIS to Host a Conference Call for Fiscal 2024 First Quarter Financial Results on August 2, 2023

STERIS (STE) announces the buyout of surgical instrumentation assets from Becton, Dickinson and Company in a $540 million transaction.

STERIS (STE) Buys Surgical Instrumentation Platform From BDX

Becton, Dickinson and Co.

Becton, Dickinson and Co. (BD) BDX, +0.96% said Tuesday it agreed to sell its surgical instrumentation platform to Steris for STE, +0.04% for $540 million, or about 3.2 times the annual revenue of $170 million for the units included in the deal. Steris said the deal is expected to add to its earnings after it closes by Sept.

Steris paying $540 mln for BD surgical instrument unit

Divestiture Advances BD2025 Strategy to Simplify Portfolio  and Focus on Higher-Growth Markets FRANKLIN LAKES, N.J. , June 20, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has signed a definitive agreement to sell its Surgical Instrumentation platform to STERIS (NYSE: STE) for $540 million.

BD to Sell Surgical Instrumentation Platform to STERIS

DUBLIN, IRELAND , June 20, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the Company has signed a definitive agreement to purchase the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from Becton, Dickinson and Company (NYSE:BDX) (“BD”) for $540 million (“the Transaction”). STERIS anticipates that the acquisition will qualify for a tax benefit related to tax deductible goodwill, with a present value of approximately $60 million.  The acquisition includes V. MuellerTM, Snowden-PencerTM and GenesisTM branded products, which are well-known providers of surgical instruments and sterilization containers to Healthcare Customers. Annual revenue for these businesses collectively for BD's fiscal year ended September 30, 2023, is projected to be approximately $170 million, with adjusted earnings before interest and taxes of approximately $45 million.

STERIS Expands Healthcare Products Offering with Acquisition of Surgical Instrumentation Assets from Becton, Dickinson and Company for $540 million

Steris (STE) reported earnings 30 days ago. What's next for the stock?

Why Is Steris (STE) Down 0.9% Since Last Earnings Report?

STERIS (STE) competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach.

STERIS (STE) Continues to Face Dull Dental Sales, Margin Woes

Steris is a company with international operations dedicated to the manufacture and sale of health products, mainly with regard to infection prevention. In my view, the future successful integration of Cantel and new acquisitions of intangibles will likely bring stable FCF generation.

Steris: FCF Generation, No Supply Chain Risks, And Undervalued

Heading into fiscal 2024, STERIS (STE) expects many of its fiscal 2023 challenges to abate, including procedure volumes and supply chain constraints.

STERIS (STE) Q4 Earnings Beat Estimates, Gross Margin Falls

Steris saw revenue rise by 14% year over year in the fourth quarter. The company upgraded guidance for fiscal 2024 revenue and earnings per share.

Why Shares of Steris Are Up Thursday

STERIS plc (NYSE:STE ) Q4 2023 Earnings Conference Call May 11, 2023 9:00 AM ET Company Participants Julie Winter - IR Daniel Carestio - President and CEO Michael Tokich - SVP and CFO Conference Call Participants Matthew Mishan - KeyBanc Dave Turkaly - JMP Securities Mike Matson - Needham & Company Michael Polark - Wolfe Research Jason Bednar - Piper Sandler Operator Good morning and welcome to the STERIS plc Fourth Quarter 2023 Earnings Conference Call. [Operator Instructions] Please also note, this event is being recorded.

STERIS plc (STE) Q4 2023 Earnings Call Transcript

Steris (STE) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.04 per share a year ago.

Steris (STE) Beats Q4 Earnings and Revenue Estimates

DUBLIN, IRELAND , May 10, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 fourth quarter and full year ended March 31, 2023. Revenue as reported for the quarter increased 14% to $1.38 billion compared with $1.21 billion in the fourth quarter of fiscal 2022. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 16% for the fourth quarter of fiscal 2023 as compared to the fourth quarter of fiscal 2022.

STERIS Announces Financial Results for Fiscal 2023 Fourth Quarter and Full Year

DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that STERIS's Board of Directors has authorized a new share buyback program for the purchase of up to $500 million of the Company's ordinary shares. Shares may be repurchased from time to time through open market transactions, including 10b5-1 plans. The repurchase program may be suspended or discontinued at any time.

STERIS Announces $500 million Share Repurchase Authorization and Declares $0.47 per share Dividend

DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today.

STERIS Appoints Esther M. Alegria, Ph.D.

DUBLIN, IRELAND, April 24, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 fourth quarter and full year financial results at 9:00 a.m. ET on May 11, 2023. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.

STERIS to Host a Conference Call for Fiscal 2023 Fourth Quarter and Full Year Financial Results on May 11, 2023

Apple

If you're willing to play the long game, they'll put money in your pocket for decades.

2 Top Dividend Stocks to Buy and Hold for 2023 and Beyond

A big earnings miss turned investors off, as did reduced guidance.

Why Steris Stock Was a Flop This Week

STERIS plc (NYSE:STE ) Q3 2023 Earnings Conference Call February 9, 2023 10:00 AM ET Company Participants Julie Winter - IR Daniel Carestio - President and CEO Michael Tokich - SVP and CFO Conference Call Participants Dave Turkaly - JMP Securities Matthew Mishan - KeyBanc Jacob Johnson - Stephens Mike Matson - Needham & Company Jason Bednar - Piper Sandler Michael Polark - Wolfe Research Matthew Mishan - KeyBanc Operator Good day, everyone, and welcome to the STERIS plc Third Quarter 2023 Conference Call. [Operator Instructions] Please also note, today's event is being recorded.

STERIS plc (STE) Q3 2023 Earnings Call Transcript

Negative foreign currency and the impact of increased supply chain and inflationary costs hurt STERIS (STE) revenues in the fiscal third quarter.

STERIS (STE) Q3 Earnings Miss Estimates, Margins Down Y/Y

Steris (STE) delivered earnings and revenue surprises of -9.01% and 4.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

News for STERIS Stock (STE)